Bloom Burton reissued their buy rating on shares of Cardiome Pharma Corp. (TSE:COM) in a report issued on Wednesday.

Shares of Cardiome Pharma Corp. (TSE:COM) opened at 4.01 on Wednesday. Cardiome Pharma Corp. has a 52 week low of $3.31 and a 52 week high of $12.25. The company’s market cap is $127.82 million. The company has a 50 day moving average price of $3.95 and a 200 day moving average price of $5.09.

Cardiome Pharma Corp. Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Stock Ratings for Cardiome Pharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp. and related stocks with our FREE daily email newsletter.